Back to results
US 12,000,004 B2Granted
Methods for molecularly characterizing cervical cell samples
AssigneeThe Government of the United States, as represented by the Secretary of the Army
InventorJane Shen-Gunther
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for molecularly characterizing cervical cell samples as being negative for intraepithelial lesion or malignancy (NILM), low-grade squamous intraepithelial lesion (LSIL), or high-grade squamous intraepithelial lesion (HSIL).
Claims9
A method of determining the methylation level of a plurality of CpG sites of a nucleic acid molecule obtained from a cell of a cervical cell sample, wherein said cell has been infected with a Human papillomavirus having a genotype selected from the group consisting of:
- 114, 91, 90, 84, 83, 81, 72, 71, 61, 54, 43, 42, 11, 6, 97, 85, 82, 73, 70, 69, 67, 66, 53, 34, 30, 26, a9, 68, 59, 58, 56, 52, 51, 45, 39, 35, 33, 31, 18, and 16 and said nucleic acid molecule has a sequence identity of at least 95% to SEQ ID NO:
- 3, which comprises
- a) converting unmethylated cytosine residues of the nucleic acid molecule to uracil by contacting the nucleic acid molecule with bisulfite to obtain a bisulfite converted nucleic acid molecule;
- b) subjecting the bisulfite converted nucleic acid molecule to polymerase chain reaction amplification using a set of primers to obtain amplified nucleic acid molecules;
- and
- c) performing an assay to determine the methylation level of each CpG site in the plurality,
- wherein the plurality of CpG sites consist of CpG 1, CpG 2, CpG 3, CpG 4, and CpG 5 of SEQ ID NO:
- 3.
5 more elements
Dependencies are inferred from the claim text.